Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 212

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

PRMT5 inhibition disrupts splicing and stemness in glioblastoma

Open access
Sachamitr, Patty, Ho, Jolene C., Ciamponi, Felipe E., Ba-Alawi, Wail, Coutinho, Fiona J., Guilhamon, Paul, Kushida, Michelle M., Cavalli, Florence M. G., Lee, Lilian, Rastegar, Naghmeh, Vu, Victoria, Sánchez-Osuna, María, Coulombe-Huntington, Jasmin, Kanshin, Evgeny, Whetstone, Heather, Durand, Mathieu, Thibault, Philippe, Hart, Kirsten, Mangos, Maria, Veyhl, Joseph, Chen, Wenjun, Tran, Nhat, Duong, Bang-Chi, Aman, Ahmed M., Che, Xinghui, Lan, Xiaoyang, Whitley, Owen, Zaslaver, Olga, Barsyte-Lovejoy, Dalia, Richards, Laura M., Restall, Ian, Caudy, Amy, Röst, Hannes L., Bonday, Zahid Quyoom, Bernstein, Mark, Das, Sunit, Cusimano, Michael D., Spears, Julian, Bader, Gary D., Pugh, Trevor J., Tyers, Mike, Lupien, Mathieu, Haibe-Kains, Benjamin, Artee Luchman, H., Weiss, Samuel, Massirer, Katlin B., Prinos, Panagiotis, Arrowsmith, Cheryl H., Dirks, Peter B. · 2021 · Nature Communications

Abstract

Glioblastoma (GBM) is a deadly cancer in which cancer stem cells (CSCs) sustain tumor growth and contribute to therapeutic resistance. Protein arginine methyltransferase 5 (PRMT5) has recently emerged as a promising target in GBM. Using two orthogonal-acting inhibitors of PRMT5 (GSK591 or LLY-283), we show that pharmacological inhibition of PRMT5 suppresses the growth of a cohort of 46 patient-derived GBM stem cell cultures, with the proneural subtype showing greater sensitivity. We show that PRMT5 inhibition causes widespread disruption of splicing across the transcriptome, particularly affecting cell cycle gene products. We identify a GBM splicing signature that correlates with the degree of response to PRMT5 inhibition. Importantly, we demonstrate that LLY-283 is brain-penetrant and significantly prolongs the survival of mice with orthotopic patient-derived xenografts. Collectively, our findings provide a rationale for the clinical development of brain penetrant PRMT5 inhibitors as treatment for GBM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-21204-5

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 212

Metadata

Authors
Sachamitr, P., Ho, J. C., Ciamponi, F. E., Ba-Alawi, W., Coutinho, F. J., Guilhamon, P., Kushida, M. M., Cavalli, F. M. G., Lee, L., Rastegar, N., Vu, V., Sánchez-Osuna, M., Coulombe-Huntington, J., Kanshin, E., Whetstone, H., Durand, M., Thibault, P., Hart, K., Mangos, M., Veyhl, J., Chen, W., Tran, N., Duong, B.-C., Aman, A. M., Che, X., Lan, X., Whitley, O., Zaslaver, O., Barsyte-Lovejoy, D., Richards, L. M., Restall, I., Caudy, A., Röst, H. L., Bonday, Z. Q., Bernstein, M., Das, S., Cusimano, M. D., Spears, J., Bader, G. D., Pugh, T. J., Tyers, M., Lupien, M., Haibe-Kains, B., Artee Luchman, H., Weiss, S., Massirer, K. B., Prinos, P., Arrowsmith, C. H., & Dirks, P. B.
Venue
Nature Communications
Published
2021-02-12
Volume
12
Issue
1
Pages
979-979
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3126515736
Cited by
212
References
14
FWCI
16.35
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PRMT5 inhibition disrupts splicing and stemness in glioblastoma. https://app.cochat.ai/papers/10.1038/s41467-021-21204-5
The paper
Sachamitr, P., Ho, J. C., Ciamponi, F. E., Ba-Alawi, W., Coutinho, F. J., Guilhamon, P., Kushida, M. M., Cavalli, F. M. G., Lee, L., Rastegar, N., Vu, V., Sánchez-Osuna, M., Coulombe-Huntington, J., Kanshin, E., Whetstone, H., Durand, M., Thibault, P., Hart, K., Mangos, M., . . . Dirks, P. B. (2021). PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nature Communications. https://doi.org/10.1038/s41467-021-21204-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.